Date :
Place : United States, San Jose
Contact Person:Ashutos Swain
Description:
The various regulatory agencies have expectations that pharmaceutical manufacturers will demonstrate control over their manufacturing equipment. The FDA's findings of deficiencies concerning equipment validation indicate the agencies expect definitive evidence that the equipment qualification and validation schedules of a facility will satisfactorily control their manufacturing processes. Examples of FDA form 483 findings for equipment qualification and validation indicate deficiencies in many of these studies.Deadline for abstracts/proposals : 19th September 2021
Organized By :Complianceonline
Keynote Speakers :
Check the event website for more details.